The Syros Pharmaceuticals CDK7 kinase inhibitor, SY-5609, is a picomolar, reversible, and highly selective molecule with slow off-rate kinetics. It follows a prior covalent clinical candidate from Syros. The molecule is >4000x selective vs. the nearest known off-target among 485 kinases profiled. Cyclin-dependent kinase inhibitors have [...]
< 1 minute read
Dec. 20, 2021
SY-5609: a CDK7 Kinase Inhibitor
SY-5609
oral picomolar & reversible CDK7 inhibitor Ph. I candidate in breast cancer comb. Therapy from previous CDK7 inhibitor SY-1365 Journal of Medicinal Chemistry Syros Pharmaceuticals Inc.